Zealand Pharma scraps obesity drug candidate, citing crowded market, Bloomberg News reports
Nov 13 (Reuters) - Zealand Pharma ZELA.CO is halting development of a potential next-generation obesity drug after concluding the market has become too crowded for it to stand out, Bloomberg News reported on Thursday, citing an interview with the company CEO. (Reporting by Mariam Sunny in Bengaluru; Editing by Vijay Kishore) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Zealand Pharma A/S
See all newsZealand falls as Berenberg cuts to 'hold' on fading survodutide hopes
Europe Research Roundup: Aixtron, Lenzing, Novo Nordisk
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up